- Obtains Good Manufacturing Practice (GMP) certification from the Indonesian Food and Drug Authority (BPOM)
- Facility equipped with advanced production systems, sterile manufacturing areas, and an end-to-end quality management system
- Connects R&D, manufacturing, and global business operations to establish a global production base
CIKARANG, Indonesia, July 21, 2026 –
PT Selatox Bio Pharma (“Selatox”) announced today that it obtained Good Manufacturing Practice (GMP) certification from the Indonesian Food and Drug Authority (BPOM) and held the official opening ceremony for its biopharmaceutical manufacturing facility in Cikarang, West Java, Indonesia.
The GMP certification formally recognizes that Selatox’s manufacturing facility and quality management system meet BPOM’s stringent requirements. With the certification, Selatox has established a stable production base for high-quality aesthetic biopharmaceutical products and is accelerating its advancement as a global manufacturing hub.
Held under the theme “Pursuing the Highest Quality, Delivering the Finest Beauty,” the event highlighted the significance of obtaining GMP certification and shared Selatox’s manufacturing competitiveness and global growth vision. The event was attended by representatives from the Ministry of Health of the Republic of Indonesia and the Indonesian Food and Drug Authority (BPOM), as well as professional medical associations, aesthetic clinics, healthcare professionals, industry partners, and other key stakeholders. Participants shared the importance of manufacturing infrastructure and quality management systems that meet stringent standards, as well as the development of skilled professionals, for the continued growth of the biopharmaceutical industry.
Selatox is a biopharmaceutical company engaged in the research, development, and manufacturing of aesthetic biopharmaceutical products. The company is developing products based on Botulinum Toxin Type A. Through the GMP certification, Selatox’s manufacturing facility and quality management system have been recognized as meeting the requirements of the Indonesian Food and Drug Authority.
The newly opened facility is equipped with advanced production systems, sterile manufacturing areas, and a quality management system covering the entire manufacturing process. The certified manufacturing facility has established production and quality management systems that comply with GMP requirements and is designed to manage quality and safety consistently at every stage, from raw material receipt and manufacturing to testing and shipment.
Joh Young Hoon, Chief Executive Officer of Selatox, said, “Obtaining GMP certification from the Indonesian Food and Drug Authority marks an important milestone, as it formally recognizes Selatox’s manufacturing facility and quality management capabilities. Based on precise manufacturing processes and rigorous quality management, we will provide high-quality products that healthcare professionals and partners can trust.”
He added, “With this certification as our starting point, we will establish a biopharmaceutical ecosystem that seamlessly connects research and development, manufacturing, and global business. We will also continue developing local professionals and internalizing advanced manufacturing technologies to grow together with Indonesia’s pharmaceutical and biotechnology industry.”
Ahn Young-jin, Director General of the Biopharmaceutical Bureau at the Ministry of Food and Drug Safety (MFDS) of the Republic of Korea, said, “On behalf of the Ministry of Food and Drug Safety (MFDS), we would like to congratulate PT Selatox Bio Pharma on the opening of its facility as a significant milestone in strengthening the strategic partnership between South Korea and Indonesia in the bio-health sector. With both Korea's MFDS and Indonesia's BPOM globally recognized for their regulatory excellence through inclusion in the WHO Listed Authority (WLA), we will continue to solidify bilateral regulatory cooperation to enhance access to advanced biopharmaceuticals and actively support industry development.
Agus Tjahajana Wirakusumah, Special Staff of Minister of Health for Health System Transformation said, “In line with the national health system transformation agenda, the Government continues to promote national health resilience by strengthening domestic production capacity, advancing technological capabilities, and enhancing collaboration among the Government, industry, and educational institutions. The presence of manufacturing facilities such as PT Selatox Bio Pharma is expected to support Indonesia's pharmaceutical self-sufficiency while enhancing the competitiveness of the national healthcare industry.”
Taruna Ikrar, Chairman of the Indonesian Food and Drug Authority (BPOM), said, “On behalf of the Indonesian Food and Drug Authority (BPOM), we would like to congratulate PT Selatox Bio Pharma on the inauguration of its biopharmaceutical manufacturing facility and the achievement of Good Manufacturing Practices (GMP) certification. This achievement reflects the company's commitment to meeting international standards for safety, quality, and efficacy, while also marking an important step in strengthening Indonesia's pharmaceutical and biopharmaceutical industry.”
With the official opening of the manufacturing facility and the acquisition of GMP certification, Selatox plans to develop Indonesia into an aesthetic biopharmaceutical hub connecting research and development, manufacturing, and global business, while growing into a global manufacturing company built on quality and trust.
